Most cancer-related deaths are caused by metastasis, the spread of cancer cells to distant tissues. This process depends on signalling proteins activated by the enzyme GGPPS (geranylgeranyl pyrophosphate synthase). Despite this, metastasis remains largely overlooked in drug discovery. We hypothesize that inhibiting GGPPS will preferentially disrupt metastasis-associated signalling, revealing GGPPS as an underexplored anti-metastatic drug target.